A deprescribing medication program to evaluate falls in older adults: methods for a randomized pragmatic clinical trial

Joshua Niznik, Stefanie P Ferreri, Lori Armistead, Benjamin Urick, Mary-Haston Vest, Liang Zhao, Tamera Hughes, J Marvin McBride, Jan Busby-Whitehead, Joshua Niznik, Stefanie P Ferreri, Lori Armistead, Benjamin Urick, Mary-Haston Vest, Liang Zhao, Tamera Hughes, J Marvin McBride, Jan Busby-Whitehead

Abstract

Background: Opioids and benzodiazepines (BZDs) are some of the most commonly prescribed medications that contribute to falls in older adults. These medications are challenging to appropriately prescribe and monitor, with little guidance on safe prescribing of these medications for older patients. Only a handful of small studies have evaluated whether reducing opioid and BZD use through deprescribing has a positive impact on outcomes. Leveraging the strengths of a large health system, we evaluated the impact of a targeted consultant pharmacist intervention to deprescribe opioids and BZDs for older adults seen in primary care practices in North Carolina.

Methods: We developed a toolkit and process for deprescribing opioids and BZDs in older adults based on a literature review and guidance from an interprofessional team of pharmacists, geriatricians, and investigators. A total of fifteen primary care practices have been randomized to receive the targeted consultant pharmacist service (n = 8) or usual care (n = 7). The intervention consists of several components: (1) weekly automated reports to identify chronic users of opioids and BZDs, (2) clinical pharmacist medication review, and (3) recommendations for deprescribing and/or alternate therapies routed to prescribers through the electronic health record. We will collect data for all patients presenting one of the primary care clinics who meet the criteria for chronic use of opioids and/or BZDs, based on their prescription order history. We will use the year prior to evaluate baseline medication exposures using morphine milligram equivalents (MMEs) and diazepam milligram equivalents (DMEs). In the year following the intervention, we will evaluate changes in medication exposures and medication discontinuations between control and intervention clinics. Incident falls will be evaluated as a secondary outcome. To date, the study has enrolled 914 chronic opioid users and 1048 chronic BZD users. We anticipate that we will have 80% power to detect a 30% reduction in MMEs or DMEs.

Discussion: This clinic randomized pragmatic trial will contribute valuable evidence regarding the impact of pharmacist interventions to reduce falls in older adults through deprescribing of opioids and BZDs in primary care settings.

Trial registration: Clinicaltrials.gov NCT04272671 . Registered on February 17, 2020.

Keywords: Benzodiazepines; Deprescribing; Falls; Older adults; Opioids; Pharmacist; Primary care.

Conflict of interest statement

Dr. Urick receives consulting fees from Cardinal Health.

All other authors have no competing interest to declare.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study Design and Overview
Fig. 2
Fig. 2
Inclusion and Exclusion Criteria

References

    1. Pretorius RW, Gataric G, Swedlund SK, et al. Reducing the risk of adverse drug events in older adults. Am Fam Physician. 2013;87(5):331–336.
    1. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701–1707. doi: 10.1056/NEJM198812293192604.
    1. Hart LA, Phelan EA, Yi JY, et al. Use of fall risk-increasing drugs around a fall-related injury in older adults: a systematic review. J Am Geriatr Soc. 2020;68(6):1334–1343. doi: 10.1111/jgs.16369.
    1. Maciejewski ML, Zepel L, Hale SL, et al. Opioid prescribing in the 2016 Medicare fee-for-service population. J Am Geriatr Soc. 2021;69(2):485–493. doi: 10.1111/jgs.16911.
    1. Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97–106. doi: 10.1176/appi.ps.201800321.
    1. Blalock SJ, Renfro CP, Robinson JM, et al. Using the Drug Burden Index to identify older adults at highest risk for medication-related falls. BMC Geriatr. 2020;20(1):208. doi: 10.1186/s12877-020-01598-5.
    1. Gray SL, Marcum ZA, Dublin S, et al. Association between medications acting on the central nervous system and fall-related injuries in community-dwelling older adults: a new user cohort study. J Gerontol A Biol Sci Med Sci. 2020;75(5):1003–1009. doi: 10.1093/gerona/glz270.
    1. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12(7):601–610. doi: 10.2174/138920011796504527.
    1. By the American Geriatrics Society Beers Criteria Update Expert Panel American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–694. doi: 10.1111/jgs.15767.
    1. Seppala LJ, Petrovic M, Ryg J, et al. STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age Ageing. 2021;50(4):1189–1199. doi: 10.1093/ageing/afaa249.
    1. Blalock SJ, Ferreri SP, Renfro CP, et al. Impact of STEADI-Rx: a community pharmacy-based fall prevention intervention. J Am Geriatr Soc. 2020;68(8):1778–1786. doi: 10.1111/jgs.16459.
    1. Robinson JM, Renfro CP, Shockley SJ, et al. Training and Toolkit resources to support implementation of a community pharmacy fall prevention service. Pharmacy (Basel) 2019;7(3):113. doi: 10.3390/pharmacy7030113.
    1. Casteel C, Blalock SJ, Ferreri S, et al. Implementation of a community pharmacy-based falls prevention program. Am J Geriatr Pharmacother. 2011;9(5):310–9.e2. doi: 10.1016/j.amjopharm.2011.08.002.
    1. Blalock SJ, Casteel C, Roth MT, et al. Impact of enhanced pharmacologic care on the prevention of falls: a randomized controlled trial. Am J Geriatr Pharmacother. 2010;8(5):428–440. doi: 10.1016/j.amjopharm.2010.09.002.
    1. Ferreri S, Roth MT, Casteel C, Demby KB, Blalock SJ. Methodology of an ongoing, randomized controlled trial to prevent falls through enhanced pharmaceutical care. Am J Geriatr Pharmacother. 2008;6(2):61–81. doi: 10.1016/j.amjopharm.2008.06.005.
    1. Bruyère Research Institute. What is deprescribing? Bruyère Research Institute. . Published 2019. Accessed April 11, 2019.
    1. Niznik JD, Collins BJ, Armistead LT, et al. Pharmacist interventions to deprescribe opioids and benzodiazepines in older adults: a rapid review. Res Soc Adm Pharm. 2021;S1551-7411(21):00270–00279.
    1. Luchen GG, Prohaska ES, Ruisinger JF, et al. Impact of community pharmacist intervention on concurrent benzodiazepine and opioid prescribing patterns. J Am Pharm Assoc (2003) 2019;59(2):238–242. doi: 10.1016/j.japh.2018.10.010.
    1. Shayegani R, Pugh MJ, Kazanis W, et al. Reducing coprescriptions of benzodiazepines and opioids in a veteran population. Am J Manag Care. 2018;24(8):e265–e269.
    1. Centers for Medicare & Medicaid Services . Chronic condition data warehouse Medicare administrative data user guide. 2017.
    1. Morden NE, Munson JC, Colla CH, et al. Prescription opioid use among disabled Medicare beneficiaries: intensity, trends, and regional variation. Med Care. 2014;52(9):852–859. doi: 10.1097/MLR.0000000000000183.
    1. Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(10):265–269. doi: 10.15585/mmwr.mm6610a1.
    1. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85–92. doi: 10.7326/0003-4819-152-2-201001190-00006.
    1. Edlund MJ, Martin BC, Russo JE, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014;30(7):557–564. doi: 10.1097/AJP.0000000000000021.
    1. Fredheim OMS, Mahic M, Skurtveit S, et al. Chronic pain and use of opioids: a population-based pharmacoepidemiological study from the Norwegian prescription database and the Nord-Trondelag health study. Pain. 2014;155(7):1213–1221. doi: 10.1016/j.pain.2014.03.009.
    1. McCauley JL, Gilbert GH, Cochran DL, et al. Prescription drug monitoring program use: national dental PBRN results. JDR Clin Trans Res. 2019;4(2):178–186.
    1. Armistead LT, Hughes TD, Larson CK, et al. Integrating targeted consultant pharmacists into a new collaborative care model to reduce the risk of falls in older adults owing to the overuse of opioids and benzodiazepines. J Am Pharm Assoc (2003) 2021;61(1):e16–e18. doi: 10.1016/j.japh.2020.08.038.
    1. Niznik JD, He H, Kane-Gill SL. Impact of clinical pharmacist services delivered via telemedicine in the outpatient or ambulatory care setting: a systematic review. Res Soc Adm Pharm. 2018;14(8):707–717. doi: 10.1016/j.sapharm.2017.10.011.
    1. Kane-Gill SL, Niznik JD, Kellum JA, et al. Use of telemedicine to enhance pharmacist services in the nursing facility. Consult Pharm. 2017;32(2):93–98. doi: 10.4140/TCP.n.2017.93.
    1. Thorpe CT, Fowler NR, Harrigan K, et al. Racial and ethnic differences in initiation and discontinuation of antidementia drugs by Medicare beneficiaries. J Am Geriatr Soc. 2016;64(9):1806–1814. doi: 10.1111/jgs.14403.
    1. Niznik JD, Zhao X, He M, et al. Factors associated with deprescribing acetylcholinesterase inhibitors in older nursing home residents with severe dementia. J Am Geriatr Soc. 2019;67(9):1871–1879. doi: 10.1111/jgs.15985.
    1. Niznik JD, Aspinall SL, Hanson LC, et al. Patterns of oral bisphosphonate deprescribing in older nursing home residents with dementia. Osteoporos Int. 2022;33(2):379–390. doi: 10.1007/s00198-021-06141-9.
    1. Farrell B, Richardson L, Raman-Wilms L, et al. Self-efficacy for deprescribing: a survey for health care professionals using evidence-based deprescribing guidelines. Res Soc Adm Pharm. 2018;14(1):18–25. doi: 10.1016/j.sapharm.2017.01.003.
    1. Ackerman AL, O'Connor PG, Doyle DL, et al. Association of an opioid standard of practice intervention with intravenous opioid exposure in hospitalized patients. JAMA Intern Med. 2018;178(6):759–763. doi: 10.1001/jamainternmed.2018.1044.
    1. Meisenberg BR, Grover J, Campbell C, et al. Assessment of opioid prescribing practices before and after implementation of a health system intervention to reduce opioid overprescribing. JAMA Netw Open. 2018;1(5):e182908. doi: 10.1001/jamanetworkopen.2018.2908.
    1. Cabelguenne D, Picard C, Lalande L, et al. Benzodiazepine dose reduction in prisoner patients: 15 years’ teamwork between psychiatrists and pharmacists. J Clin Pharm Ther. 2018;43(6):807–812. doi: 10.1111/jcpt.12709.
    1. Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert Opin Drug Saf. 2014;13(7):919–934. doi: 10.1517/14740338.2014.925444.
    1. Pharmacy Quality Alliance. PQA opioid measures. (2021), Accessed 7th Jul 2021.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren